Press Releases Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
0.186 ^USD	-3.93%		-0.05%	+27.92%

04-03	North American Morning Briefing : Powell Awaited -2-	DJ
03-28	Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galera Adopts Limited Duration Stockholder Rights Agreement	05-03	GL
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates	03-28	GL
Galera Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	03-27	PU
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates	11-14	GL
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates	11-14	AQ
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update	23-10-31	GL
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update	23-10-31	AQ
Galera Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	23-09-21	PU
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem	23-09-18	GL
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-09-05	GL
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates	23-08-14	GL
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates	23-08-14	AQ
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese	23-08-09	GL
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting	23-06-05	GL
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting	23-06-05	AQ
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer	23-05-18	GL
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer	23-05-18	AQ
Galera Therapeutics : Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with decades of experience successfully launching and commercializing new oncology products - Form 8-K	23-05-11	PU
GALERA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-11	AQ
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates	23-05-11	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Galera Therapeutics, Inc.

Equities

GRTX

US36338D1081

Press Releases

Filters